Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Oregon Health and Science University
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Gerd Bobe, Oregon State University
ClinicalTrials.gov Identifier:
NCT00764270
First received: October 1, 2008
Last updated: April 3, 2017
Last verified: April 2017

October 1, 2008
April 3, 2017
August 2011
November 2011   (Final data collection date for primary outcome measure)
hs-CRP [ Time Frame: 12,20 & 32 weeks ]
Same as current
Complete list of historical versions of study NCT00764270 on ClinicalTrials.gov Archive Site
8-lso-PGF2a [ Time Frame: 12, 20 & 32 weeks ]
Same as current
Not Provided
Not Provided
 
The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease
The Role of R-alpha Lipoic Acid in Treatment of Atherosclerotic Vascular Disease
The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors in people with documented heart disease and increased levels of inflammation.
Not Provided
Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Atherosclerosis
Dietary Supplement: Crossover of R-alpha lipoic acid and placebo
300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of placebo or 300 mg R-alpha-lipoic acid for 12 weeks
  • Active Comparator: Lipoic acid treatment
    Participants take lipoic acid with a washout period before or after placebo.
    Intervention: Dietary Supplement: Crossover of R-alpha lipoic acid and placebo
  • Placebo Comparator: Placebo treatment
    Participants take placebo with a washout period before or after lipoic acid treatment
    Intervention: Dietary Supplement: Crossover of R-alpha lipoic acid and placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
50
December 2017
November 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented congestive heart disease (CHD)(defined as at least one significant coronary stenosis > 50% on angiography, or history of documented myocardial infarction)
  • Not diagnosed with unstable angina, uncontrolled hypertension, heart failure, recent myocardial infarction (within last six months)
  • Not taking insulin or oral hypoglycemic agents, anti-inflammatory drugs other than aspirin, or hormone replacement therapy
  • On stable doses for four weeks prior to entry of lipid-lowering therapy (statins), aspirin, and angiotensin-converting enzyme inhibitors or other blood pressure medications. P
  • No tobacco use within 3 months of the study
  • No laboratory evidence of renal, hepatic, or hematological abnormalities
  • Not currently taking vitamin or antioxidant supplements, including R-alpha lipoic acid, except standard multivitamin/mineral supplements containing not more than the Daily Value (DV) of the vitamins and minerals;
  • Elevated levels of urinary and plasma F2-isoprostanes
  • Elevated plasma levels of hs-CRP
Sexes Eligible for Study: All
50 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00764270
AT002034-2
5P01AT002034 ( US NIH Grant/Contract Award Number )
Yes
Not Provided
Not Provided
Not Provided
Gerd Bobe, Oregon State University
Oregon State University
  • Oregon Health and Science University
  • National Center for Complementary and Integrative Health (NCCIH)
Principal Investigator: Balz Frei, PhD Oregon State University
Oregon State University
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP